Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sysmex ( (JP:6869) ) just unveiled an update.
Sysmex Corporation’s board has approved a share repurchase program and subsequent cancellation of the repurchased stock as part of its mid-term management plan through March 2029. The initiative is aimed at improving capital efficiency, enhancing shareholder returns, and supporting future growth investments, aligning capital policy with long-term strategic objectives.
The company plans to buy back up to 30 million common shares, representing about 4.81% of outstanding stock, for a maximum of ¥30 billion via market purchases on the Tokyo Stock Exchange between March 6 and September 18, 2026. All acquired shares will be cancelled on September 30, 2026, effectively reducing the share count and potentially increasing earnings per share and shareholder value over time.
The most recent analyst rating on (JP:6869) stock is a Buy with a Yen1622.00 price target. To see the full list of analyst forecasts on Sysmex stock, see the JP:6869 Stock Forecast page.
More about Sysmex
Sysmex Corporation is a Japan-based medical device company specializing in diagnostic instruments, reagents, and related software for clinical laboratories and healthcare providers. The company focuses on hematology and in-vitro diagnostics, serving hospitals and testing centers worldwide while maintaining a listing on the Tokyo Stock Exchange.
Average Trading Volume: 3,939,659
Technical Sentiment Signal: Sell
Current Market Cap: Yen913.9B
Learn more about 6869 stock on TipRanks’ Stock Analysis page.